Email This Release
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Terms of Use
|
© 2024 Business Wire